
MiMedx Group (MDXG) Stock Forecast & Price Target
MiMedx Group (MDXG) Analyst Ratings
Bulls say
MiMedx Group Inc. has revised its 2025 revenue estimate upward to $387.3 million, reflecting strong second-quarter results and a growing surgical business. In the second quarter, MiMedx reported revenue of $98.6 million, demonstrating a year-over-year growth of approximately 13%, primarily driven by its wound care portfolio and surgical offerings. Notably, the wound portfolio contributed $64.5 million, up 12% year-over-year, while the surgical sector increased by 15%, totaling $34.1 million, indicating robust demand for the company's regenerative biomaterial products.
Bears say
MiMedx Group Inc experienced a decline in gross margins, dropping from approximately 83% to 81% in 2Q25, which raises concerns regarding production efficiencies and product mix. Despite the company's long-term guidance suggesting low double-digit percentage year-over-year revenue growth and an adjusted EBITDA margin above 20%, previous performance indicates challenges in maintaining profitability. Furthermore, potential adverse changes in reimbursement rates from the Centers for Medicare & Medicaid Services (CMS) could negatively impact MiMedx's revenue and overall business viability.
This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.
MiMedx Group (MDXG) Analyst Forecast & Price Prediction
Start investing in MiMedx Group (MDXG)
Order type
Buy in
Order amount
Est. shares
0 shares